{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T21:42:27Z","timestamp":1778017347638,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1980,11,1]],"date-time":"1980-11-01T00:00:00Z","timestamp":341884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1980,11]]},"DOI":"10.1007\/bf00434401","type":"journal-article","created":{"date-parts":[[2004,11,11]],"date-time":"2004-11-11T05:54:20Z","timestamp":1100152460000},"page":"137-142","source":"Crossref","is-referenced-by-count":22,"title":["A single dose study of nabilone, a synthetic cannabinoid"],"prefix":"10.1007","volume":"71","author":[{"given":"Richard M.","family":"Glass","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. H.","family":"Uhlenhuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank W.","family":"Hartel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles R.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian W.","family":"Fischman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1037\/h0047161","volume":"53","author":"BM Bass","year":"1956","unstructured":"Bass BM (1956) Development and evaluation of a scale for measuring social acquiescence. J Abnorm Soc Psychol 53:296?299","journal-title":"J Abnorm Soc Psychol"},{"key":"CR2","first-page":"89","volume":"13","author":"B Brauzer","year":"1973","unstructured":"Brauzer B, Goldstein BJ (1973) Symptomatic volunteers: Another patient dimension for clinical trials. J Clin Pharmacol 13:89?98","journal-title":"J Clin Pharmacol"},{"key":"CR3","volume-title":"Psychological measurements in psychopharmacology: Modern problems in pharmacopsychiatry, vol 7","author":"LR Derogatis","year":"1974","unstructured":"Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi S (1974) The Hopkins symptom checklist (HSCL): A measure of primary symptom dimensions. In: Pichot P (ed) Psychological measurements in psychopharmacology: Modern problems in pharmacopsychiatry, vol 7. Karger, Basel"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000136463","volume":"11","author":"WG Drew","year":"1974","unstructured":"Drew WG, Miller LL (1974) Cannabis: Neural mechanisms and behavior ? a theoretical review. Pharmacology 11:12?23","journal-title":"Pharmacology"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3928\/0048-5713-19780901-09","volume":"8","author":"MW Dysken","year":"1978","unstructured":"Dysken MW, Merry W, Davis JM (1978) Anticholinergic psychosis. Psychiatric Annals 8:452?456","journal-title":"Psychiatric Annals"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1360-0443.1973.tb01264.x","volume":"68","author":"MK El-Yousef","year":"1973","unstructured":"El-Yousef MK, Janowsky DS, Davis JM, Rosenblatt JE (1973) Induction of severe depression by physostigmine in marijuana intoxicated individuals. Br J Addict 68:321?325","journal-title":"Br J Addict"},{"key":"CR7","volume-title":"Eysenck personality iventory","author":"HJ Eysenck","year":"1968","unstructured":"Eysenck HJ, Eysenck SBG (1968) Eysenck personality iventory. Educational and Industrial Testing Service. San Diego, California"},{"key":"CR8","first-page":"161","volume":"24","author":"LF Fabre","year":"1978","unstructured":"Fabre LF, McLendon DM, Stark P (1978) Nabilone, a cannabinoid, in the treatment of anxiety: An open-label and double-blind study. Curr Ther Res 24:161?169","journal-title":"Curr Ther Res"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00431981","volume":"66","author":"MW Fischman","year":"1979","unstructured":"Fischman MW, Schuster CR (1979) The effects of chlorpromazine and pentobarbital on behavior maintained by electric shock or point loss avoidance in humans. Psychopharmacology 66:3?11","journal-title":"Psychopharmacology"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0091-3057(76)90184-2","volume":"4","author":"M Fischman","year":"1976","unstructured":"Fischman M, Smith R, Schuster CR (1976) The effects of chlorpromazine on avoidance and escape responding in humans. Pharmacol Biochem Behav 4:111?114","journal-title":"Pharmacol Biochem Behav"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cpt1975172121","volume":"17","author":"FR Freeman","year":"1975","unstructured":"Freeman FR, Rosenblatt JE, El-Yousef M (1975) Interaction of physostigmine and delta-9-tetrahydrocannabinol in man. Clin Pharmacol Ther 17:121?126","journal-title":"Clin Pharmacol Ther"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJM197906073002302","volume":"300","author":"TS Herman","year":"1979","unstructured":"Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE (1979) Superiority of nabilone over prochloperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300:1295?1297","journal-title":"N Engl J Med"},{"key":"CR13","first-page":"619","volume":"37","author":"RL Ilaria","year":"1978","unstructured":"Ilaria RL, Fann WE (1978) Nabilone, a cannabinol derivative, in anxiety neurosis. Fed Proc 37:619","journal-title":"Fed Proc"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/cpt1975186720","volume":"18","author":"L Lemberger","year":"1975","unstructured":"Lemberger L, Rowe H (1975) Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharmacol Ther 18:720?726","journal-title":"Clin Pharmacol Ther"},{"key":"CR15","first-page":"157","volume":"108","author":"MD Low","year":"1973","unstructured":"Low MD, Klonoff H, Marcus A (1973) The neurophysiological basis of the marijuana experience. Can Med Assoc J 108:157?164","journal-title":"Can Med Assoc J"},{"key":"CR16","first-page":"230","volume":"19","author":"LE McCarthy","year":"1977","unstructured":"McCarthy LE, Borison HL (1977) Antiemetic activity of nabilone, a cannabinol derivative, reversed by naloxone in awake cats. Pharmacologist 19:230","journal-title":"Pharmacologist"},{"key":"CR17","volume-title":"Non-specific factors in drug therapy","author":"DM McNair","year":"1968","unstructured":"McNair DM, Kahn JR, Droppleman LF, Fisher S (1968) Patient acquiescence and drug effects. In Rickels K (ed) Non-specific factors in drug therapy. C. C. Thomas, Springfield, Illinois"},{"key":"CR18","volume-title":"Profile of mool states","author":"DM McNair","year":"1971","unstructured":"McNair DM, Lorr M, Droppleman LF (1971) Profile of mool states. Educational and Industrial Testing Service, San Diego, California"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cpt197823154","volume":"23","author":"S Nakano","year":"1978","unstructured":"Nakano S, Gillespie HK, Hollister LE (1978) A model for evaluation of anti-anxiety drugs with the use of experimentally induced stress: Comparison of nabilone and diazepam. Clin Pharmacol Ther 23:54?62","journal-title":"Clin Pharmacol Ther"},{"key":"CR20","volume-title":"Marijuana and health. Fifth report to the U. S. Congress","author":"National Institute on Drug Abuse","year":"1975","unstructured":"National Institute on Drug Abuse (1975) Marijuana and health. Fifth report to the U. S. Congress, United States Government Printing Office, Washington D. C."},{"key":"CR21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1974.01760090020004","volume":"30","author":"B Prusoff","year":"1974","unstructured":"Prusoff B, Klerman GL (1974) Differentiating depressed from anxious neurotic outpatients. Arch Gen Psychiatry 30:302?309","journal-title":"Arch Gen Psychiatry"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00005053-196901000-00010","volume":"148","author":"A Raskin","year":"1969","unstructured":"Raskin A, Schilterbrandt J, Reatig N, McKeon JJ (1969) Replication of factors of psychopathology in interview, ward behavior, and self-report ratings of hospitalized depressives. J Neur Ment Disorders 148:87?98","journal-title":"J Neur Ment Disorders"},{"key":"CR23","first-page":"210","volume":"17","author":"P Stark","year":"1975","unstructured":"Stark P, Archer RA (1975) Preclinical pharmacologic profile of a psychoactive cannabinoid. Pharmacologist 17:210","journal-title":"Pharmacologist"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1176\/ajp.134.6.659","volume":"134","author":"EH Uhlenhuth","year":"1977","unstructured":"Uhlenhuth EH (1977) Evaluating anti-anxiety agents in humans: Experimental paradigms. Am J Psychiatry 134:659?662","journal-title":"Am J Psychiatry"},{"key":"CR25","volume-title":"Predictability in psychopharmacology: Preclinical and clinical correlations","author":"EH Uhlenhuth","year":"1975","unstructured":"Uhlenhuth EH, Stern M, Schuster CR, Domizi D (1975) Diazepam: Efficacy and toxicity as revealed by a small sample research strategy. In: Sudilovsky A, Gershon S, Beer B (eds) Predictability in psychopharmacology: Preclinical and clinical correlations. Raven Press, New York"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1037\/h0028329","volume":"72","author":"WA Wagenaar","year":"1969","unstructured":"Wagenaar WA (1969) Note on the construction of digram-balanced Latin squares. Psychol Bull 72:384?386","journal-title":"Psychol Bull"},{"key":"CR27","first-page":"149","volume":"2","author":"EJ Williams","year":"1949","unstructured":"Williams EJ (1949) Experimental designs balanced for the estimation of residual effects of treatments. Austr J Scientific Res A 2:149?168","journal-title":"Austr J Scientific Res A"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00434401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00434401\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00434401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T04:07:51Z","timestamp":1624853271000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00434401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1980,11]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1980,11]]}},"alternative-id":["BF00434401"],"URL":"https:\/\/doi.org\/10.1007\/bf00434401","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1980,11]]}}}